A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
← catalyst calendarNCT06305247 · readout in 579 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
36actual
Sites
11
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-04-03 | actual | When the study began enrolling |
| Primary completion | 2028-03-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-03-20 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma
- Head and Neck Squamous Cell Carcinoma
- Pancreatic Ductal Adenocarcinoma
- Colorectal Cancer
- Solid Tumor
Interventions
- Drug: IPN01194
- Drug: IPN01194
Primary outcomes
what the primary-completion date above is the date OFPhase 1: Percentage of participants with dose limiting toxicity (DLT)
measured Within 28 days of first dose
Phase 1: Percentage of participants experiencing Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TE SAEs)
measured At 30 days following the last administration of study intervention
Phase 1: Percentage of participants with dose interruptions and permanent treatment discontinuations
measured At 30 days following the last administration of study intervention
Phase 2a: Objective response rate (ORR)
measured At end of treatment (up to approximately 32 months)
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed